Inhibition of MDR1 overcomes resistance to brentuximab vedotin in Hodgkin lymphoma

PURPOSE: In classical Hodgkin lymphoma (HL), the malignant Reed-Sternberg cells express the cell surface marker CD30. Brentuximab vedotin (BV) is an antibody-drug conjugate that selectively delivers a potent cytotoxic agent, monomethyl auristatin E (MMAE), to CD30-positive cells. Although BV elicits...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Chen, Robert, Herrera, Alex F., Hou, Jessie, Chen, Lu, Wu, Jun, Guo, Yuming, Synold, Timothy W., Ngo, Vu N., Puverel, Sandrine, Mei, Matthew, Popplewell, Leslie, Yi, Shuhua, Song, Joo Y., Tao, Shu, Wu, Xiwei, Chan, Wing C, Forman, Stephen J., Kwak, Larry W., Rosen, Steven T., Newman, Edward M.
Format: Artigo
Sprog:Inglês
Udgivet: 2019
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7056527/
https://ncbi.nlm.nih.gov/pubmed/31811017
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-1768
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker